Earth Science Tech, Inc. (ETST) Reports Fiscal First Quarter 2027 Financial Results for the Period Ended June 30, 2026
Earth Science Tech, Inc. (OTC: ETST) reported fiscal first-quarter 2027 results for the period ended June 30, 2026. Revenue rose to $9.0 million from $8.8 million. Net income increased 57% to $715,697, with diluted EPS at $0.003. Operating cash flow rose 108% to $707,131. The company repurchased and retired 3.7 million shares and said key subsidiaries were profitable.
How this was made
The 30-second read
Why it matters
This is a primary quarterly results release with multiple tradable datapoints: profitability up year over year, operating cash flow up sharply, balance sheet growth, and a larger-than-prior-year share repurchase. It also tees up governance and potential uplisting discussion at the Aug. 31 annual meeting.
Market read
Traders can reassess ETST’s near-term fundamentals and capital return trajectory based on the reported net income, operating cash flow, asset growth, and expanded buyback activity, while monitoring the Aug. 31 proxy-driven catalysts.
What to watch
The article flags potential Series B preferred cancellation and a possible exchange uplisting, but provides no terms or timing certainty; traders may overreact to optionality ahead of the Aug. 31 meeting.
Background
Earth Science Tech, Inc. is an OTC strategic holding company focused on a vertically integrated healthcare platform (compounding pharmacy, telehealth, and fulfillment).
Ticker impact
ETST reported fiscal Q1 ended June 30, 2026 results, including 57% net income growth to $715,697 and diluted EPS rising to $0.003.
Likely modest positive bias for the next session(s), with follow-through dependent on OTC liquidity and any uplisting/proxy vote headlines.
The article provides concrete quarterly financials (income, operating cash flow, assets) and a capital return action (3.7M shares retired), but it does not include guidance, margins detail beyond gross profit, or a clear catalyst beyond the scheduled annual meeting.
Market effects
Reinforces the narrative that vertically integrated telehealth and compounding pharmacy models can generate operating cash flow, but impact is likely limited given microcap/OTC scale.
No specific regional read-through beyond Miami-based issuer operations.
Low, as the disclosure is company-specific and OTC-listed.
Counterpoint
The absolute earnings and EPS are extremely small in dollar terms, so the percentage gains may not translate into durable valuation support without clearer forward guidance.
Key entities
- companyEarth Science Tech, Inc.
OTC-listed strategic holding company reporting fiscal first quarter 2027 results for the period ended June 30, 2026.
- personGiorgio R. Saumat
CEO and Chairman who commented on operating leverage, capital discipline, and planned strategic initiatives.
- securitySeries B Preferred Stock
Preferred equity class proposed for cancellation as an agenda item at the Aug. 31 annual meeting.
